Physician profile
Zumara Ayers
NPI 1285022574
$2,036.20
in general payments reported to CMS, 2019-2025
14 companies · $489 in 2025
The $489 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $347 · 2023: $520 · 2024: $409 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $649.14 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $388.17 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $322.80 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $264.55 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $131.41 | 2022-2024 | |
| Lilly USA, LLC | $54.49 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $53.20 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $38.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.32 | 2022 | |
| Renalytix Ai, INC. | $22.59 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $21.25 | 2025 | |
| Amarin Pharma, INC. | $20.74 | 2021 | |
| Horizon Therapeutics Plc | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zumara Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.